Skip to main content

Table 1 Characteristics of NSCLC patients with brain metastasis

From: The efficacy and roles of combining temozolomide with whole brain radiotherapy in protection neurocognitive function and improvement quality of life of non-small-cell lung cancer patients with brain metastases

Characteristics Total (%) RCT (%) RT (%) P
All patients 238 (100) 129 (100) 109 (100)  
Gender
 Female 102 (42.9) 60 (46.5) 42 (38.5) 0.22
 Male 136 (57.1) 69 (53.5) 67 (61.5)  
Smoking
 Never 108 (45.4) 63 (48.8) 45 (41.3) 0.24
 Current/former 130 (54.6) 66 (51.2) 64 (58.7)  
Age
 ≤60 96 (40.3) 58 (45.0) 38 (35.9) 0.11
 >60 142 (59.7) 71 (55.0) 71 (65.1)  
Histology
 Adenocarcinoma 227 (95.4) 123 (95.3) 104 (95.4) 0.98
 Non-adenocarcinoma 11 (4.6) 6 (4.7) 5 (4.6)  
ECOG PS
 0–1 188 (79.0) 101 (78.3) 87 (79.8) 0.77
 2–3 50 (21.0) 28 (21.7) 22 (20.2)  
Prior chemotherapy
 NO 92 (38.7) 51 (39.5) 41 (37.6) 0.76
 YES 146 (61.3) 78 (60.5) 68 (62.4)  
Number of BM
 ≤3 65 (27.3%) 33 (25.6%) 32 (29.4%) 0.52
 >3 173 (72.7%) 96 (74.4%) 77 (70.6%)  
Extracranial metastases
 NO 93 (39.1%) 48 (37.2%) 45 (41.3%) 0.52
 YES 145 (60.9%) 81 (62.8%) 64 (58.7%)  
Primary disease control
 NO 31 (13.0%) 20 (15.5%) 11 (10.1%) 0.22
 YES 207 (87.0%) 109 (84.5%) 98 (89.9%)  
RTOG RPA class
 ClassI 50 (21.0%) 31 (24.0%) 19 (17.4%) 0.21
 ClassII + III 188 (79.0%) 98 (76.0%) 90 (82.6%)  
RTOG GPA grade
 0–2 143 (60.1%) 74 (57.4%) 69 (63.3%) 0.35
 2.5–4 95 (39.9%) 55 (42.6%) 40 (36.7%)  
  1. Abbreviations: Eastern Cooperative Oncology Group performance status ECOG PS, Brain metastasis BM, the Radiation Therapy Oncology Group RTOG, recursive partitioning analysis RPA, graded prognostic assessment GPA